Yüklüyor......
Erelzi<sup>®</sup> – biosimilar of etanercept in the treatment of rheumatic diseases and psoriasis (Resolution of the Expert Panel)
Introduction of biosimilars of biological disease-modifying antirheumatic drugs (bDMARs) into clinical practice has significantly expanded the availability of bDMARD therapy for a wide range of patients with chronic immuno-inflammatory diseases.In 2020, the first biosimilar etanercept Erelzi®, was r...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Russo |
| Baskı/Yayın Bilgisi: |
IMA-PRESS LLC
2021-08-01
|
| Seri Bilgileri: | Современная ревматология |
| Konular: | |
| Online Erişim: | https://mrj.ima-press.net/mrj/article/view/1183 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|